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Supplementary materials and methods. 
 
Sunitinib resistance inheritance experiment 
4T1 tumours displaying acquired (responsive cohort) or innate (non-responsive cohort) 
resistance to sunitinib treatment in vivo were removed at 1300 mm3 in size, minced, and 
tumour derived cells cultured in high glucose Dulbecco's modified eagle medium (DMEM) 
(Sigma, Gillingham, UK), supplemented with 10% FCS (PAA, Cambridge, UK) and 2mM L-
glutamine (Gibco, Paisley, UK), for 2 weeks. 2.5x105 4T1-Luc cells, from these cultures, 
suspended in Optimem (Gibco) and in a volume of 100 μL, were injected into the third 
mammary fat pad of anaesthetised 8-week-old female Balb/C mice. After a 1-week tumour 
establishment period, mice received either 40 mg sunitinib (Selleck Chemicals, USA) per kg 
body weight in phosphate buffered saline (PBS) (Sigma) and 3.72% DMSO (Sigma) or the 
drug vehicle only. The tumour growth was measured by daily caliper measurements. 
 
 
